JP2010523562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523562A5 JP2010523562A5 JP2010502114A JP2010502114A JP2010523562A5 JP 2010523562 A5 JP2010523562 A5 JP 2010523562A5 JP 2010502114 A JP2010502114 A JP 2010502114A JP 2010502114 A JP2010502114 A JP 2010502114A JP 2010523562 A5 JP2010523562 A5 JP 2010523562A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- pyrido
- tetrahydro
- methyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 208000004296 neuralgia Diseases 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 37
- 208000002193 Pain Diseases 0.000 claims description 32
- 206010029240 Neuritis Diseases 0.000 claims description 18
- -1 cycloheteroalkyl Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 13
- 208000037765 diseases and disorders Diseases 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000008482 osteoarthritis Diseases 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 208000020925 Bipolar disease Diseases 0.000 claims description 8
- 208000003251 Pruritus Diseases 0.000 claims description 8
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010043269 Tension headache Diseases 0.000 claims description 7
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 208000004371 toothache Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 230000000155 isotopic effect Effects 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 230000003959 neuroinflammation Effects 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 208000028683 bipolar I disease Diseases 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 230000007803 itching Effects 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 4
- 208000036273 reactive airway disease Diseases 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 206010003399 Arthropod bite Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- 206010069632 Bladder dysfunction Diseases 0.000 claims description 3
- 206010006784 Burning sensation Diseases 0.000 claims description 3
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims description 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010015150 Erythema Diseases 0.000 claims description 3
- 208000034347 Faecal incontinence Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 3
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 3
- 206010049949 Intercostal neuralgia Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000002472 Morton Neuroma Diseases 0.000 claims description 3
- 208000020059 Morton neuralgia Diseases 0.000 claims description 3
- 206010068106 Occipital neuralgia Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 206010036105 Polyneuropathy Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 3
- 206010040744 Sinus headache Diseases 0.000 claims description 3
- 208000004078 Snake Bites Diseases 0.000 claims description 3
- 208000003589 Spider Bites Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000002146 bilateral effect Effects 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 3
- 201000007637 bowel dysfunction Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 230000035606 childbirth Effects 0.000 claims description 3
- 231100000321 erythema Toxicity 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 210000003127 knee Anatomy 0.000 claims description 3
- 208000037805 labour Diseases 0.000 claims description 3
- 230000005906 menstruation Effects 0.000 claims description 3
- 230000027939 micturition Effects 0.000 claims description 3
- 201000009985 neuronitis Diseases 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 3
- 208000019629 polyneuritis Diseases 0.000 claims description 3
- 210000003497 sciatic nerve Anatomy 0.000 claims description 3
- 230000001953 sensory effect Effects 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 231100000331 toxic Toxicity 0.000 claims description 3
- 230000002588 toxic effect Effects 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
- RKPAFGOLZJQTPL-IBGZPJMESA-N (2r)-2-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound N1=CC(C)=CC=C1N1CC2=C(N[C@@H](CO)C=3C=CC=CC=3)N=CN=C2CC1 RKPAFGOLZJQTPL-IBGZPJMESA-N 0.000 claims description 2
- COHPLRFPNJNJIX-GOSISDBHSA-N (2s)-2-(6-methoxypyridin-3-yl)-2-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NC(OC)=CC=C1[C@@H](CO)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 COHPLRFPNJNJIX-GOSISDBHSA-N 0.000 claims description 2
- WPBBTBJCOJRQNE-QGZVFWFLSA-N (2s)-2-[[6-(5-chloropyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]-2-(6-methoxypyridin-3-yl)ethanol Chemical compound C1=NC(OC)=CC=C1[C@@H](CO)NC1=NC=NC2=C1CN(C=1N=CC(Cl)=CC=1)CC2 WPBBTBJCOJRQNE-QGZVFWFLSA-N 0.000 claims description 2
- XTUGYSDHPHABIN-LJQANCHMSA-N (2s)-2-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]-2-[4-(trifluoromethyl)phenyl]ethanol Chemical compound N1=CC(C)=CC=C1N1CC2=C(N[C@H](CO)C=3C=CC(=CC=3)C(F)(F)F)N=CN=C2CC1 XTUGYSDHPHABIN-LJQANCHMSA-N 0.000 claims description 2
- RKPAFGOLZJQTPL-LJQANCHMSA-N (2s)-2-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound N1=CC(C)=CC=C1N1CC2=C(N[C@H](CO)C=3C=CC=CC=3)N=CN=C2CC1 RKPAFGOLZJQTPL-LJQANCHMSA-N 0.000 claims description 2
- PUIPLPMBTAVSBG-GOSISDBHSA-N (3r)-3-(6-methoxypyridin-3-yl)-3-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]propan-1-ol Chemical compound C1=NC(OC)=CC=C1[C@@H](CCO)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 PUIPLPMBTAVSBG-GOSISDBHSA-N 0.000 claims description 2
- SSNDZSZPTDFBHC-LJQANCHMSA-N (3r)-3-(6-methylpyridin-3-yl)-3-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]propan-1-ol Chemical compound N1=CC(C)=CC=C1N1CC2=C(N[C@H](CCO)C=3C=NC(C)=CC=3)N=CN=C2CC1 SSNDZSZPTDFBHC-LJQANCHMSA-N 0.000 claims description 2
- JYXGOVPRQNIYKV-QGZVFWFLSA-N (3r)-3-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]-3-[6-(trifluoromethyl)pyridin-3-yl]propan-1-ol Chemical compound N1=CC(C)=CC=C1N1CC2=C(N[C@H](CCO)C=3C=NC(=CC=3)C(F)(F)F)N=CN=C2CC1 JYXGOVPRQNIYKV-QGZVFWFLSA-N 0.000 claims description 2
- LELBPCNKKRJYQV-UHFFFAOYSA-N 1-(6-methoxypyridin-3-yl)propan-1-ol Chemical compound CCC(O)C1=CN=C(OC)C=C1 LELBPCNKKRJYQV-UHFFFAOYSA-N 0.000 claims description 2
- DTQUOODAYMQTHN-UHFFFAOYSA-N 2-[[6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]-2-pyridin-3-ylethanol Chemical compound N1=CC(C)=CC=C1N1CC2=C(NC(CO)C=3C=NC=CC=3)N=CN=C2CC1 DTQUOODAYMQTHN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 2
- VCVJHUNWPOOPQN-GFCCVEGCSA-N 6-(5-chloropyridin-2-yl)-n-[(1r)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=NC(=CC=1)C(F)(F)F)C(C=1C2)=NC=NC=1CCN2C1=CC=C(Cl)C=N1 VCVJHUNWPOOPQN-GFCCVEGCSA-N 0.000 claims description 2
- VCVJHUNWPOOPQN-LBPRGKRZSA-N 6-(5-chloropyridin-2-yl)-n-[(1s)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@@H](C)C=1C=NC(=CC=1)C(F)(F)F)C(C=1C2)=NC=NC=1CCN2C1=CC=C(Cl)C=N1 VCVJHUNWPOOPQN-LBPRGKRZSA-N 0.000 claims description 2
- CMEYRTUYGFNHBD-HXUWFJFHSA-N 6-(5-chloropyridin-2-yl)-n-[(r)-cyclopropyl-[6-(trifluoromethyl)pyridin-3-yl]methyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=NC(C(F)(F)F)=CC=C1[C@@H](C1CC1)NC1=NC=NC2=C1CN(C=1N=CC(Cl)=CC=1)CC2 CMEYRTUYGFNHBD-HXUWFJFHSA-N 0.000 claims description 2
- CMEYRTUYGFNHBD-FQEVSTJZSA-N 6-(5-chloropyridin-2-yl)-n-[(s)-cyclopropyl-[6-(trifluoromethyl)pyridin-3-yl]methyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=NC(C(F)(F)F)=CC=C1[C@H](C1CC1)NC1=NC=NC2=C1CN(C=1N=CC(Cl)=CC=1)CC2 CMEYRTUYGFNHBD-FQEVSTJZSA-N 0.000 claims description 2
- DGCROPBFIBILRA-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-(1-naphthalen-1-ylethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 DGCROPBFIBILRA-UHFFFAOYSA-N 0.000 claims description 2
- XVVMIRNQEFEULE-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-(1-phenylpropyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC=CC=1C(CC)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 XVVMIRNQEFEULE-UHFFFAOYSA-N 0.000 claims description 2
- UUWHBMBIWZIRLD-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-(1-pyridin-2-ylethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC=NC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 UUWHBMBIWZIRLD-UHFFFAOYSA-N 0.000 claims description 2
- KHKPRVFTDKPHCV-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-(1-pyridin-3-ylethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CN=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 KHKPRVFTDKPHCV-UHFFFAOYSA-N 0.000 claims description 2
- QVWXUUHKIMGPFG-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-(1-pyridin-4-ylethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=NC=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 QVWXUUHKIMGPFG-UHFFFAOYSA-N 0.000 claims description 2
- MEMSDESZGNUHMN-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-(2,2,2-trifluoro-1-phenylethyl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CC2=C(NC(C=3C=CC=CC=3)C(F)(F)F)N=CN=C2CC1 MEMSDESZGNUHMN-UHFFFAOYSA-N 0.000 claims description 2
- XNAFMMCWOUXFDU-CQSZACIVSA-N 6-(5-methylpyridin-2-yl)-n-[(1r)-1-(2-methylpyrimidin-5-yl)ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=NC(C)=NC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 XNAFMMCWOUXFDU-CQSZACIVSA-N 0.000 claims description 2
- ICLOKAIXSUXTKZ-CQSZACIVSA-N 6-(5-methylpyridin-2-yl)-n-[(1r)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=NC(=CC=1)C(F)(F)F)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 ICLOKAIXSUXTKZ-CQSZACIVSA-N 0.000 claims description 2
- PODLAPNQWXJKQM-MRXNPFEDSA-N 6-(5-methylpyridin-2-yl)-n-[(1r)-1-phenylethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 PODLAPNQWXJKQM-MRXNPFEDSA-N 0.000 claims description 2
- XVVMIRNQEFEULE-IBGZPJMESA-N 6-(5-methylpyridin-2-yl)-n-[(1s)-1-phenylpropyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 XVVMIRNQEFEULE-IBGZPJMESA-N 0.000 claims description 2
- VEHRIESAOMHDBK-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[1-(4-methylsulfonylphenyl)ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 VEHRIESAOMHDBK-UHFFFAOYSA-N 0.000 claims description 2
- HNFLMSORXFUDLB-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[1-[2-(trifluoromethyl)phenyl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 HNFLMSORXFUDLB-UHFFFAOYSA-N 0.000 claims description 2
- RDXICZFIIAPTMJ-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[1-[3-(trifluoromethyl)phenyl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 RDXICZFIIAPTMJ-UHFFFAOYSA-N 0.000 claims description 2
- KMHMFCXBSABZLF-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[1-[4-(1,2,4-triazol-1-yl)phenyl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(N2N=CN=C2)C=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 KMHMFCXBSABZLF-UHFFFAOYSA-N 0.000 claims description 2
- KPQNVEFDANSNEJ-UHFFFAOYSA-N 6-(5-methylpyridin-2-yl)-n-[1-[4-(trifluoromethyl)phenyl]ethyl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 KPQNVEFDANSNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000005945 imidazopyridyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- BSHIAFMHMKJSPC-MRXNPFEDSA-N n-[(1r)-1-(3-methoxyphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC([C@@H](C)NC=2C=3CN(CCC=3N=CN=2)C=2N=CC(C)=CC=2)=C1 BSHIAFMHMKJSPC-MRXNPFEDSA-N 0.000 claims description 2
- CJYBSPSAYUVDMV-CYBMUJFWSA-N n-[(1r)-1-(4-chlorophenyl)ethyl]-6-(5-chloropyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=CC(Cl)=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(Cl)C=N1 CJYBSPSAYUVDMV-CYBMUJFWSA-N 0.000 claims description 2
- NAJWMPSVESSMGN-OAHLLOKOSA-N n-[(1r)-1-(4-chlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=CC(Cl)=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 NAJWMPSVESSMGN-OAHLLOKOSA-N 0.000 claims description 2
- DUPYPBQTFOKCSC-OAHLLOKOSA-N n-[(1r)-1-(4-fluorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=CC(F)=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 DUPYPBQTFOKCSC-OAHLLOKOSA-N 0.000 claims description 2
- YGIOSPPWRLVBJP-MRXNPFEDSA-N n-[(1r)-1-(4-methoxyphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1[C@@H](C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 YGIOSPPWRLVBJP-MRXNPFEDSA-N 0.000 claims description 2
- JSQPMXXGCBUZST-QGZVFWFLSA-N n-[(1r)-1-(4-methylphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@H](C)C=1C=CC(C)=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 JSQPMXXGCBUZST-QGZVFWFLSA-N 0.000 claims description 2
- BSHIAFMHMKJSPC-INIZCTEOSA-N n-[(1s)-1-(3-methoxyphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC([C@H](C)NC=2C=3CN(CCC=3N=CN=2)C=2N=CC(C)=CC=2)=C1 BSHIAFMHMKJSPC-INIZCTEOSA-N 0.000 claims description 2
- NAJWMPSVESSMGN-HNNXBMFYSA-N n-[(1s)-1-(4-chlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@@H](C)C=1C=CC(Cl)=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 NAJWMPSVESSMGN-HNNXBMFYSA-N 0.000 claims description 2
- DUPYPBQTFOKCSC-HNNXBMFYSA-N n-[(1s)-1-(4-fluorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 DUPYPBQTFOKCSC-HNNXBMFYSA-N 0.000 claims description 2
- YGIOSPPWRLVBJP-INIZCTEOSA-N n-[(1s)-1-(4-methoxyphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1[C@H](C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 YGIOSPPWRLVBJP-INIZCTEOSA-N 0.000 claims description 2
- JSQPMXXGCBUZST-KRWDZBQOSA-N n-[(1s)-1-(4-methylphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 JSQPMXXGCBUZST-KRWDZBQOSA-N 0.000 claims description 2
- CLBSVPYCZLWSCF-UHFFFAOYSA-N n-[1-(2,4-dichlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 CLBSVPYCZLWSCF-UHFFFAOYSA-N 0.000 claims description 2
- HUNKNRMFRKNUAR-UHFFFAOYSA-N n-[1-(2,4-difluorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(F)C=C(F)C=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 HUNKNRMFRKNUAR-UHFFFAOYSA-N 0.000 claims description 2
- YCUDKFILFQRHLI-UHFFFAOYSA-N n-[1-(2-chlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC=C(Cl)C=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 YCUDKFILFQRHLI-UHFFFAOYSA-N 0.000 claims description 2
- GGDAJJXTRCEWJF-UHFFFAOYSA-N n-[1-(2-fluorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC=C(F)C=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 GGDAJJXTRCEWJF-UHFFFAOYSA-N 0.000 claims description 2
- VUJYFXHHIVJFMA-UHFFFAOYSA-N n-[1-(2-methoxy-5-methylphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound COC1=CC=C(C)C=C1C(C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 VUJYFXHHIVJFMA-UHFFFAOYSA-N 0.000 claims description 2
- KCOZDLJGLHTDIQ-UHFFFAOYSA-N n-[1-(2-methoxyphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC=C1C(C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 KCOZDLJGLHTDIQ-UHFFFAOYSA-N 0.000 claims description 2
- STMMULZVHSKPDR-UHFFFAOYSA-N n-[1-(3,5-difluorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C(F)=CC(F)=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 STMMULZVHSKPDR-UHFFFAOYSA-N 0.000 claims description 2
- IUPSCNROFMBCEW-UHFFFAOYSA-N n-[1-(3-chlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC(Cl)=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 IUPSCNROFMBCEW-UHFFFAOYSA-N 0.000 claims description 2
- DQEIWRKPVLQBJW-UHFFFAOYSA-N n-[1-(3-fluoro-4-methoxyphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=C(F)C(OC)=CC=C1C(C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 DQEIWRKPVLQBJW-UHFFFAOYSA-N 0.000 claims description 2
- GJAUWURFLVNMPO-UHFFFAOYSA-N n-[1-(3-fluorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=CC(F)=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 GJAUWURFLVNMPO-UHFFFAOYSA-N 0.000 claims description 2
- YVOGFFAHHJCXSZ-UHFFFAOYSA-N n-[1-(4-bromophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(Br)C=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 YVOGFFAHHJCXSZ-UHFFFAOYSA-N 0.000 claims description 2
- CNUGQOFQIIDDCR-UHFFFAOYSA-N n-[1-(4-chloro-3-fluorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(Cl)C(F)=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 CNUGQOFQIIDDCR-UHFFFAOYSA-N 0.000 claims description 2
- NAJWMPSVESSMGN-UHFFFAOYSA-N n-[1-(4-chlorophenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C=C(Cl)C=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 NAJWMPSVESSMGN-UHFFFAOYSA-N 0.000 claims description 2
- RHMCVUQKMIMGDA-UHFFFAOYSA-N n-[1-(4-ethoxyphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=CC(OCC)=CC=C1C(C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 RHMCVUQKMIMGDA-UHFFFAOYSA-N 0.000 claims description 2
- WTEFMFHLHIXCDB-UHFFFAOYSA-N n-[1-(4-ethylphenyl)ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=CC(CC)=CC=C1C(C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 WTEFMFHLHIXCDB-UHFFFAOYSA-N 0.000 claims description 2
- UFOPSRNDIOHMMG-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)NC(C=1C2)=NC=NC=1CCN2C1=CC=C(C)C=N1 UFOPSRNDIOHMMG-UHFFFAOYSA-N 0.000 claims description 2
- UWKZKGGSAWUHAF-UHFFFAOYSA-N n-[1-[4-(2-methylpropyl)phenyl]ethyl]-6-(5-methylpyridin-2-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound C1=CC(CC(C)C)=CC=C1C(C)NC1=NC=NC2=C1CN(C=1N=CC(C)=CC=1)CC2 UWKZKGGSAWUHAF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 210000001738 temporomandibular joint Anatomy 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000001364 causal effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92160307P | 2007-04-02 | 2007-04-02 | |
| US92160407P | 2007-04-02 | 2007-04-02 | |
| US60/921,603 | 2007-04-02 | ||
| US60/921,604 | 2007-04-02 | ||
| PCT/US2008/004202 WO2008123963A1 (en) | 2007-04-02 | 2008-03-31 | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523562A JP2010523562A (ja) | 2010-07-15 |
| JP2010523562A5 true JP2010523562A5 (enExample) | 2011-04-07 |
| JP5396379B2 JP5396379B2 (ja) | 2014-01-22 |
Family
ID=39831232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010502114A Expired - Fee Related JP5396379B2 (ja) | 2007-04-02 | 2008-03-31 | ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8653091B2 (enExample) |
| EP (1) | EP2136639B1 (enExample) |
| JP (1) | JP5396379B2 (enExample) |
| CA (1) | CA2682162C (enExample) |
| ES (1) | ES2566387T3 (enExample) |
| WO (1) | WO2008123963A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076345B2 (en) * | 2007-04-17 | 2011-12-13 | Evotec Ag | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof |
| CA2747170C (en) * | 2008-12-19 | 2017-07-18 | Abbott Laboratories | Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EP2619204A4 (en) * | 2010-09-21 | 2014-08-27 | Merck Sharp & Dohme | TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS |
| CA2857302C (en) | 2011-12-15 | 2020-08-25 | Novartis Ag | Use of inhibitors of the activity or function of pi3k |
| JP6458429B2 (ja) * | 2014-09-30 | 2019-01-30 | 大日本印刷株式会社 | 導電材充填貫通電極基板及びその製造方法 |
| AU2015359626B2 (en) | 2014-12-09 | 2020-07-23 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| US10183937B2 (en) | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| EP3325490B1 (en) * | 2015-07-23 | 2019-12-18 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
| CN113727758A (zh) * | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| KR102921974B1 (ko) | 2019-05-31 | 2026-02-05 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 아미노 퀴나졸린 유도체 |
| KR102923602B1 (ko) * | 2019-05-31 | 2026-02-06 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 피리도피리미딘 유도체 |
| TWI793704B (zh) * | 2020-08-06 | 2023-02-21 | 大陸商北京泰德製藥股份有限公司 | Sos1抑制劑、包含其的藥物組合物及其用途 |
| EP4251273B1 (en) * | 2020-11-27 | 2025-03-12 | Chiesi Farmaceutici S.p.A. | Phthalazine derivatives as p2x3 inhibitors |
| WO2022112491A1 (en) * | 2020-11-27 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| CA3196333A1 (en) * | 2020-11-27 | 2022-06-02 | Claudio FIORELLI | Amino quinazoline derivatives as p2x3 inhibitors |
| WO2022166974A1 (zh) * | 2021-02-08 | 2022-08-11 | 武汉人福创新药物研发中心有限公司 | 吡啶并嘧啶酮类衍生物及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3424760A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| US3424761A (en) | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| DE2502588A1 (de) | 1975-01-23 | 1976-07-29 | Troponwerke Dinklage & Co | Basisch substituierte derivate des 7-amino-2-chinolons, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| DE69834842T2 (de) | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen |
| DE69836563T2 (de) | 1997-12-22 | 2007-05-16 | Bayer Pharmaceuticals Corp., West Haven | INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN |
| AU778393B2 (en) | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| EP1252160B1 (en) * | 2000-01-14 | 2006-08-16 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methanocarba cycloalkyl nucleoside analogues |
| US6531478B2 (en) | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| AU8066701A (en) | 2000-07-20 | 2002-02-05 | Neurogen Corp | Capsaicin receptor ligands |
| KR100554813B1 (ko) | 2001-01-02 | 2006-02-22 | 에프. 호프만-라 로슈 아게 | 알파 1에이/비 아드레날린성 수용체 길항제로서의퀴나졸론 유도체 |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| JP4629978B2 (ja) | 2002-02-25 | 2011-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療に有用な１，４−二置換ベンゾ縮合シクロアルキル尿素化合物 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| GB0225908D0 (en) | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| WO2004056774A2 (en) | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| ATE517885T1 (de) | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
| CA2606760C (en) | 2005-05-04 | 2014-12-23 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions |
-
2008
- 2008-03-31 EP EP08727238.1A patent/EP2136639B1/en not_active Not-in-force
- 2008-03-31 WO PCT/US2008/004202 patent/WO2008123963A1/en not_active Ceased
- 2008-03-31 JP JP2010502114A patent/JP5396379B2/ja not_active Expired - Fee Related
- 2008-03-31 US US12/594,364 patent/US8653091B2/en not_active Expired - Fee Related
- 2008-03-31 ES ES08727238.1T patent/ES2566387T3/es active Active
- 2008-03-31 CA CA2682162A patent/CA2682162C/en not_active Expired - Fee Related